Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Nitrosoureas
Nitrosoureas: Current Status and New Developments covers the preclinical and clinical status of nitrosoureas. The book presents preclinical studies on the development of the nitrosoureas; combination chemotherapy with nitrosoureas plus other anticancer drugs against animal tumors; EORTC studies with novel nitrosoureas; and chemical decomposition of chloroethylnitrosoureas. The text also includes preclinical studies on the metabolism of nitrosoureas; DNA crosslinking and the origin of sensitivity to chloroethylnitrosoureas; modification of DNA and RNA bases; and carbamoylating activity of nitrosoureas. Clinical studies on subacute and chronic toxicities associated with nitrosourea therapy; th...
Introduction to Clinical Oncology
9780121978020 Cancer and Chemotherapy, Volume II: Introduction to Clinical Oncology provides the basic framework for understanding antineoplastic drugs. The use of chemotherapeutics in the treatment of the most common human malignancies, including leukemias and lymphomas, is discussed. Solid tumors such as those affecting the breast and lung, head and neck, brain and spinal cord are also considered. Comprised of 17 chapters, this volume begins with an overview of leukemias and lymphomas, including their incidence, pathology, and clinical features. The discussion then turns to solid tumors such as breast and lung carcinoma; head and neck cancers; cancer of the brain and spinal cord; gastroint...
Current Catalog
First multi-year cumulation covers six years: 1965-70.
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischem...
Antineoplastic Agents
Cancer and Chemotherapy, Volume III: Antineoplastic Agents is a collection of articles that deals with the treatment of cancer using drugs. The collection describes the various drugs that are used, the therapeutic approaches being taken, and agents that are being developed. Part I is a general review of anti-cancer drugs as regards their action mechanisms, pharmacokinetics, pharmacology, known toxicities, and clinical utility. These drugs include alkylating agents such as mitomycin C and nitrosoureas; plant alkaloids such as maytansine; antibiotics such as anthracyclines; platinum-containing complexes; antimetabolites; and hormones. Part II examines the molecular pharmacology of some major d...
Cisplatin
Cisplatin: Current Status and New Developments is a collection of papers presented at a symposium sponsored by the University of Alabama in Birmingham Comprehensive Cancer Center and the Bristol Laboratories in Syracuse, ?ew York, and held on September 27-28, 1979, in Atlanta, Georgia. The symposium provided a forum for assessing developments with regards to cisplatin as an anticancer drug, with emphasis on its clinical application in a wide variety of adult and pediatric malignancies as well as the mechanism by which the drug appears to cause tumor cell death. Comprised of 39 chapters, this book begins with a preclinical overview of cisplatin, focusing on its mechanism of action, pharmacolo...
